Kratom and 7-OH Rescheduling: What the DEA’s 2026 Action Means for Consumers and Treatment
Kratom and products containing 7-hydroxymitragynine (7-OH) have received increasing attention from public health professionals, lawmakers, and people who use these products. On July 1, 2026, the U.S. Drug Enforcement Administration (DEA) announced its intent to temporarily place 7-OH and three related substances into Schedule I of the Controlled Substances Act. The announcement represents a significant change in how certain high-potency 7-OH products may be regulated in the United States. However, it is important to understand what is—and is not—being scheduled.


